{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12"}]}],"title":"MRD negative at 10^(-5)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}],"title":"MRD negative at 10^(-6)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"}],"units":"Participants"}],"description":"MRD is the small number myeloma cells surviving in the bone marrow after a clinical response has been measured and the patient is in remission. MRD negativity will be determined by deep sequencing of genomic deoxyribonucleic acid from bone marrow samples using rearranged Ig locus-specific primers (Adaptive, Seattle, WA). The MRD rate after 4 cycles of of Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone (KRDI) is the percentage of patients who are MRD negative at 10\\^(-5) and 10\\^(-6), meaning that no MRD was detected in samples of 100,000 cells and 1,000,000 cells, respectively.","groups":[{"description":"All participants will receive 4 cycles of induction therapy. Based on the recommendation of investigators, participants may or may not proceed to an autologous stem cell transplant (SCT) after cycles 1-4. Each cycle is 28 days in length (see dosing details below.)\n\nFor patient undergoing upfront stem cell transplant (SCT): 4 cycles followed by stem cell collection, high-dose chemotherapy, and autologous SCT followed by 2 cycles (called consolidation).\n\nFor patients deferring SCT following collection: 4 cycles followed by stem cell collection followed by 4 additional cycles.\n\nCarfilzomib: 56 mg/m2 IV on days 1, 8,15 Lenalidomide 25 mg orally (PO) on Days 1-21 Isatuximab: 10 mg/kg IV weekly for cycles 1-2 (days 1, 8, 15, 22), then every 2 weeks for cycles 3-6 (days 1 and 15), and monthly (day 1) thereafter Dexamethasone: 20 mg orally (PO) administered day of and day after carfilzomib and isatuximab (days 1, 2, 8, 9, 15, and 16; days 22 and 23 during cycles 1-2 only).\n\nPatients achieving a partial response (PR) or greater will be stratified by cytogenetic risk and receive either high risk (Lenalidomide 10 mg orally (PO) Day 1-21 Carfilzomib 56 mg/m2 or last tolerated dose IV Days 1, 15 Isatuximab 10 mg/kg IV Day 1) or low risk maintenance therapy (Lenalidomide 10 mg orally (PO) Day 1-21).","id":"OG000","title":"Induction"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"After cycle 4, 28 patients out of 47 patients evaluable for response had evaluable MRD data.","reportingStatus":"POSTED","timeFrame":"112 Days (4 Cycles)","title":"Minimal Residual Disease (MRD) Rate After 4 Cycles Induction Therapy","type":"SECONDARY","unitOfMeasure":"Participants"}